In conclusion, the present study suggests that the ALC at diagnosis (X1.0 Â 10 9 /l) is predictive of response to chemotherapy (especially R-CHOP) and can be a good prognostic factor for DLBCL patients. Host immunocompetence at the time of diagnosis will be an important parameter of prognosis in patients with DLBCL. 
Treatment outcome in adult acute lymphoblastic leukemia (ALL) has shown little improvement over the years with complete remission (CR) rates of 80-85% and leukemia-free survival of 30-40%. [1] [2] [3] The results of treatment have significantly improved in Tcell and mature B-cell ALL, without much change in B-precursor ALL. 4 Attempts to improve outcome include high-dose intensification, stem cell transplantation and risk-adapted therapy based on identified prognostic markers or minimal residual disease. However, in developing countries where state funding for expensive health-care interventions is lacking, it is important that treatment modifications should be cost effective. 5 This is a retrospective analysis of the outcome of 210 adult patients with ALL (X15 years) treated with a modified German ALL (GMALL) protocol from 1994 to 2003. The aim of this study was to identify biologic and clinical prognostic markers for adult ALL in the Indian population and compare this with Caucasian data.
The diagnosis of ALL was based on morphological evaluation of May Grunwald Giemsa-stained smears of bone marrow and confirmed by cytochemistry and immunophenotypic analysis. Central nervous system (CNS) involvement was diagnosed if more than 5 cells per ml were present in a nontraumatic cerebro spinal fluid (CSF) at diagnosis and if lymphoblasts were identified on cytospin. Karyotypic analysis was not carried out systematically in this cohort of patients.
After preinduction with steroids for 1 week, phase I induction was given over 4 weeks with vincristine (VCR), daunorubicin (DNR), L-asparaginase (ASP) and prednisolone (PDN). Bone marrow examination was done after completion of the phase I induction to assess remission. Phase II induction consisted of cyclophosphamide (Cyclo) and four courses of cytosine (Ara C) combined with CNS-directed therapy using intrathecal methotrexate (MTx) and prophylactic cranial radiotherapy. Consolidation consisted of two 5-day courses of Ara C (75 mg/m 2 ) and etoposide (50 mg/m 2 ) along with a single dose of intrathecal MTx (12.5 mg). This was followed by re-induction with VCR, DNR, dexamethasone (Dexa), Cyclo and Ara C over a period of 6 weeks. The final maintenance consisted of daily mercaptopurine (6-MP) and weekly oral MTx for 24 months. This maintenance was intensified with monthly pulses of VCR 2 mg, Dexa 10 mg/m 2 for 5 days and intrathecal MTx 12.5 mg once in 3 months (Figure 1 ). The differences with the GMALL protocol are: six thioguanine omitted during phase II induction and consolidation and addition of VCR þ Dexa pulses every 4 weeks þ intrathecal MTx once in 3 months during maintenance for a total period of 24 months. The management of febrile neutropenic episodes was carried out according to standard guidelines.
Good PDN response (GPR) was defined as o1000 blasts/ml in the peripheral blood on day 8 of starting treatment. At the end of phase I induction, patients were considered to be in CR if the peripheral blood count was normal with no blasts in the peripheral smear or CSF and no lymphoblasts in marrow aspiration smears. Relapse was defined as recurrence of lymphoblasts or localized leukemic infiltrate at any site.
Differences in means and proportions were tested using either a Mann-Whitney-U test or a w 2 statistic test. Overall survival (OS) was defined as time from initiation of treatment till death or date of last follow-up. Event-free survival (EFS) was defined from initiation of treatment till first event or date of last follow-up. Induction failures, default, relapse, deaths in CR were considered as events. Disease-free survival (DFS) was defined as time from achieving CR to relapse, or date of last follow-up. The probability of OS, EFS and DFS was estimated using KaplanMeier method. EFS for prognostic variables were compared using log rank tests and relevance studied using univariate and multivariate Cox regression analysis.
There were 159 males and 51 females with a median age of 22.5 years (range: 15-66). Median white blood cell (WBC) count at diagnosis was 13.5 Â 10 9 /l (range: 1-471) and 84 patients (40%) had a white cell count 430 Â 10 9 /l. Mediastinal mass was seen at diagnosis in 30 (14.3%) patients, whereas CNS involvement at diagnosis was present in 23 (11%). On the basis of immunophenotypic analysis, 129 (64%) were classified as B-lineage ALL and 71 (35.5%) as T-lineage ALL (data were not available in 10 patients).
Eight patients discontinued treatment during induction and were considered nonevaluable. Among the 202 patients, 166 (82.2%) patients achieved CR, whereas 25 (12.4%) had resistant disease and 11 (5.5%) expired during induction. The day 8 PDN response was evaluable in 200 patients and could not be assessed in 10 either because of low WBC counts or prior treatment with steroids for more than a week. One hundred and fifty-five patients (77.5%) showed a GPR, whereas 45 (22.5%) were classified as poor PDN responders. The main cause of induction death was infection in 10 patients and intracranial hemorrhage in one. Two patients developed cerebral cortical venous thrombosis secondary to ASP. Four patients developed severe uncontrolled diabetes while on ASP and PDN, leading to discontinuation of ASP.
Of the 166 patients who achieved CR, five underwent an allogeneic stem cell transplant for either an underlying complex cytogenetics (four) or a positive Philadelphia chromosome (one). Twelve (7.2%) discontinued treatment or were lost to follow-up, whereas four (2.4%) died in CR. All deaths were related to infection. At a median follow-up of 55 months (range: 31-108), 76 patients (45.8%) continue to remain in remission with 69 patients (41.6%) having relapsed at a median period of 14 months (range: 1-69). The sites of relapse included bone marrow in 57 (82.6%), CNS in four (5.7%) and testes in one (1.7%). Four (5.7%) relapsed in bone marrow and CNS and three (4.3%) patients had relapses at other sites (Table 1) .
After a median follow-up of 55 months (range: 1-108 months), the 5-year OS is 3873.5%, 5-year EFS is 3673.5% and 5-year DFS is 4474%. The 5-year EFS was 3274.4% for B-lineage ALL and 3876.2% for T-lineage ALL (P ¼ 0.034).
Age had a significant impact on survival with 5-year EFS of 46.7% for patients o20 years, 33.38% for patients between 20 and 30 years and 14% for patients 440 years of age (P ¼ 0.005). PDN response had a significant impact on prognosis with a 5-year EFS of 45.6% for good responders and only 10.6% for poor responders (Po0.000). In patients who failed to achieve CR at the end of the initial phase of induction, the 5-year EFS was only 4%. Patients with CNS disease had a lower 5-year EFS of 21%, whereas it was 37% in patients without CNS disease This figure outlines the protocol scheme used to treat patients with adult ALL in this series of patients.
Letters to the Editor (P ¼ 0.054). WBC count at diagnosis and gender did not significantly influence the EFS. A univariate Cox regression analysis identified age 435 years, B lineage, CNS disease at diagnosis, poor PDN response and residual disease at the end of phase I of induction therapy as having an adverse prognostic impact on treatment outcome. A multivariate analysis revealed the unfavorable impact of the following variables -B-lineage ALL, CNS disease at diagnosis, poor PDN response and failure to achieve remission after initial induction ( Table 2) . The remission induction rates with conventional four-drug induction in our series was 82% which is comparable to published data from the West.
2,3 The 5-year EFS and OS in this series is comparable to previous reported outcomes in adult ALL with the GMALL 02/84 study of 562 patients which reported a 7-year leukemia-free survival of 39% and the PETHEMA ALL 93 study with EFS of 41% at 4 years. Intensification of therapy with high-dose MTx and Ara C is expensive and may not be practical for most patients in the developing world. We augmented the final maintenance therapy with monthly pulses of VCR and Dexa and extended CNS-directed therapy with three monthly intrathecal MTx. With the modified protocol, the estimated 5-year OS, EFS and DFS of the patients treated were 38, 36 and 44%, respectively. It is possible that the higher proportion of T-cell ALL in our patient population may have contributed to the improved outcome in the absence of high-dose consolidation chemotherapy. There is very little published data on the outcome of adult ALL in India. A small series of 42 patients treated with an aggressive regime has reported an OS of 41.9% at the end of 5 years. 6 These changes to the maintenance without intensification may be a useful cost-effective strategy for B-lineage ALL in developing countries and needs to be studied further in a randomized trial. Older age has consistently been shown to be an adverse prognostic feature in adult ALL as was seen in our study.
1 B-lineage ALL was an adverse prognostic factor for EFS in our study. In childhood ALL, PDN response has been recognized as an independent prognostic marker. 7 The GIEMMA ALL 0288 randomized study revealed PDN response to be an independent prognostic factor for OS, CCR and DFS in adult ALL and in this cohort a similar impact was seen with 45.6% EFS in PDN good response and only 10.6% in patients with a poor PDN response (Figure 2 ). The identification of poor PDN response as an independent prognostic marker provides us with a useful tool to evaluate early therapeutic response and change the post-remission approach where possible. WBC count stratified with type of leukemia is a strong prognostic factor as shown in German trials. 8 A WBC count 430 Â 10 9 /l was seen as an adverse prognostic factor in B-lineage ALL, but it did not impact survival in T-cell ALL: WBC count at diagnosis was not as significant as other variables in this series because 35% of the patients had T-ALL. CNS disease at diagnosis was also seen to impact survival as seen with other large studies. This series shows that it is possible to achieve results comparable to those achieved in the West in adults with ALL in the developing world without the addition of high-dose intensive chemotherapy.
A Bajel, B George, V Mathews, A Viswabandya, ML Kavitha, A Srivastava and M Chandy Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India E-mail: mammen@cmcvellore.ac.in Table 1 Treatment outcome in adult ALL This shows the Kaplan-Meier survival curve in 200 patients with adult ALL in whom the PDN response could be assessed at day 8. The glycosyl-phosphatidylinositol-anchored folate receptor (FR) has been widely recognized as a potential target for the selective delivery of therapeutic agents to pathological tissues. 1 This is because of the narrow tissue specificity of FR expression in normal tissues, its restricted expression at the luminal surface of epithelial cells that is inaccessible to the circulation, the ability of the receptor to bind and internalize both small and particulate chemical conjugates of folic acid and the ability of the receptor to mediate various types of immunotherapy. The a subtype of FR has served as a therapeutic target in many promising pre-clinical and clinical studies of carcinomas, whereas FRb expressed in activated macrophage has proven to be a promising target in the treatment of inflammatory diseases. 2 We have previously reported that the expression of FRb is limited to the myelomonocytic lineage and that its expression is increased during neutrophil maturation and during the activation of macrophage; 3, 4 however, among normal hematopoietic cells, only the receptor expressed in activated macrophage is functional in having the ability to bind folate. 4, 5 FRb is also expressed in a functional form in approximately 70% of acute myelogenous leukemia (AML) in which it is frequently coexpressed with CD34. 6 These observations suggest that FRb is a potential target for drug delivery to AML cells, but prospects of its clinical utility are limited by the variable and the frequently low expression of the receptor in the leukemic cells of AML patients. 6 Our previous in vitro studies in both AML cell lines and primary AML cells have demonstrated that all-trans retinoic acid (ATRA) acts directly on the FRb gene to selectively upregulate its expression 6, 7 and that this effect is potentiated by innocuous histone deacetylase (HDAC) inhibitors, including valproic acid (VPA). 8 The receptor induction sensitized AML cells to FRtargeted drugs including folate-coated liposomal doxorubicin 5 and the antifolate, dideazatetrahydrofolate. 8 Treatment with ATRA also increased the survival of mice that were injected KG1 AML cells in their peritoneal cavity upon treatment with FR-targeted liposomal doxorubicin. 5 Combination treatment with innocuous agents that upregulate FRb in AML cells is, therefore, an attractive means of addressing a major limitation of experimental FR-targeted therapies in AML.
Two important considerations must precede the design of clinical studies to test whether treatment with ATRA, either alone or in combination with an HDAC inhibitor, will upregulate FRb in the leukemic cells in the bone marrow of AML patients. First, since maintenance of AML is dependent on a smaller population of leukemic stem cells that possess extensive proliferative capacity, it is important to test whether FRbexpressing AML cells from patients are capable of proliferation in the marrow. Second, induction of FRb by ATRA alone or in combination with an HDAC inhibitor must be demonstrated in an appropriate animal model of AML. These questions are addressed in this study using the non-obese diabetic mouse with severe combined immunodeficiency (NOD-SCID mouse) model of AML.
Leukemic stem cells in peripheral blood or bone marrow as well as in several AML cell lines can engraft with high efficiency in the bone marrow of NOD-SCID mice, which have been exposed to a sublethal dose of radiation.
9 These mice not only lack B-and T-cell functions, but also have compromised natural killer cell and macrophage activities. The engrafting leukemia stem cells are termed SCID leukemia-initiating cells (SL-ICs). SL-ICs from AMLs (M1, M2, M4 and M5) were largely CD34 þ / CD38À and phenotypically similar to normal hematopoietic SCID-repopulating cells.
10,11 These cells could persist through serial transplantations and were able to proliferate and differentiate into leukemoblasts in the cascading process of SL-IC-clonogenic progenitors (CFUs)-blast cells, producing a disease in the engrafted animals identical to that in the donor.
10,11
Since a quantitative method to distinguish between human and mouse FRb protein is unavailable, FRb expression in the engrafted human cells in NOD-SCID mice was distinguished from that of the host marrow cells by using real-time reverse transcription-PCR assays that were specific for the mRNAs of the human receptor and for human GAPDH (internal control). RNA was isolated from pre-and post-engraftment samples of primary AML cells from three patients for identification and quantification of human FRb mRNA and normalized in each sample to the mRNA for human GAPDH ( Table 1 ). The results show that FRb þ AML cells could engraft and be enriched in the marrow and could represent a proliferating population of the leukemic cells.
To test the ability of ATRA to upregulate FRb in AML cells engrafted in mouse bone marrow, MV4-11 cells were chosen rather than primary patient AML cells to have a sufficient
